90 related articles for article (PubMed ID: 15714423)
1. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.
Gavrila A; Hsu W; Tsiodras S; Doweiko J; Gautam S; Martin L; Moses AC; Karchmer AW; Mantzoros CS
Clin Infect Dis; 2005 Mar; 40(5):745-9. PubMed ID: 15714423
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
3. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
5. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
[TBL] [Abstract][Full Text] [Related]
6. Normalization of metabolic syndrome using fenofibrate, metformin or their combination.
Nieuwdorp M; Stroes ES; Kastelein JJ;
Diabetes Obes Metab; 2007 Nov; 9(6):869-78. PubMed ID: 17924869
[TBL] [Abstract][Full Text] [Related]
7. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
Slama L; Lanoy E; Valantin MA; Bastard JP; Chermak A; Boutekatjirt A; William-Faltaos D; Billaud E; Molina JM; Capeau J; Costagliola D; Rozenbaum W
Antivir Ther; 2008; 13(1):67-76. PubMed ID: 18389900
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Piccinni MN; Fogari E; Salvadeo S; Ciccarelli L; Fogari R
Diabetes Res Clin Pract; 2005 Jul; 69(1):5-13. PubMed ID: 15955382
[TBL] [Abstract][Full Text] [Related]
9. [HAART influences the lipids].
Behrens G
MMW Fortschr Med; 2009 Apr; 151(18):36-8. PubMed ID: 19769073
[No Abstract] [Full Text] [Related]
10. Pioglitazone in a subgroup of patients with type 2 diabetes meeting the criteria for metabolic syndrome.
Lester JW; Fernandes AW
Int J Clin Pract; 2005 Feb; 59(2):134-42. PubMed ID: 15854187
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients.
Marx N; Wöhrle J; Nusser T; Walcher D; Rinker A; Hombach V; Koenig W; Höher M
Circulation; 2005 Nov; 112(18):2792-8. PubMed ID: 16246947
[TBL] [Abstract][Full Text] [Related]
12. Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome.
Murdock DK; Jansen D; Juza RM; Kersten M; Olson K; Hendricks B
WMJ; 2006 Jul; 105(5):22-5. PubMed ID: 16933409
[TBL] [Abstract][Full Text] [Related]
13. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
14. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
Watts GF; Ji J; Chan DC; Ooi EM; Johnson AG; Rye KA; Barrett PH
Clin Sci (Lond); 2006 Sep; 111(3):193-9. PubMed ID: 16700661
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
16. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial.
Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H
Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome.
Grinspoon S
Clin Infect Dis; 2003; 37 Suppl 2():S85-90. PubMed ID: 12942379
[TBL] [Abstract][Full Text] [Related]
19. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
[TBL] [Abstract][Full Text] [Related]
20. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.
Karalliedde J; Viberti GC
Diabetes; 2007 May; 56(5):e3; author reply e4. PubMed ID: 17470560
[No Abstract] [Full Text] [Related]
[Next] [New Search]
